Back to top
more

ResMed (RMD)

(Real Time Quote from BATS)

$243.82 USD

243.82
505,837

-0.46 (-0.19%)

Updated Nov 4, 2024 03:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) given its better-than-expected results and robust SaaS business performance in the fiscal first quarter.

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

ResMed (RMD) Q1 Earnings Top Estimates, Margins Decline

by Zacks Equity Research

ResMed (RMD) reports better-than-expected earnings and revenues with robust demand for sleep and respiratory care devices driving Q1 top line.

ResMed (RMD) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

ResMed (RMD) delivered earnings and revenue surprises of 11.85% and 5.15%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Hill-Rom (HRC) for Now

by Zacks Equity Research

Investors are optimistic about Hill-Rom (HRC) owing to strategic buyouts and continued expansion efforts in the digital health space.

ResMed (RMD) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).

Here's Why You Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors are optimistic about ResMed (RMD) owing to new product launches in the SDB market and strong sales of mask products.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

ResMed (RMD)-Backed Landmark ALASKA Study Favors PAP Therapy

by Zacks Equity Research

A late-breaking abstract from ResMed (RMD) supported landmark ALASKA study reported that treatment with PAP therapy improves the likelihood of longevity in sleep apnea patients

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ResMed's (RMD) AirSense 11 to Boost Sleep Apnea Digitalization

by Zacks Equity Research

ResMed's (RMD) new launch will make therapy setup easier for patients and help clinicians offer care more efficiently.

ResMed (RMD) Hits New 52-Week High: What's Behind the Rally?

by Zacks Equity Research

Investors are optimistic about ResMed's (RMD) potential in digital health and its strong emphasis on product development.

Here's Why You Should Add Henry Schein (HSIC) to Your Portfolio

by Zacks Equity Research

Strong performance by the Dental, Medical & Technology and Value-Added Services segments is driving Henry Schein's (HSIC) top line.

    ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Down

    by Zacks Equity Research

    Increased demand for sleep devices and masks, including recovery of core sleep patient flow, drove ResMed's (RMD) fiscal fourth-quarter growth.

    Zacks.com featured highlights include: Vista Outdoor, Canon, Apollo Medical, Tyler Tech and ResMed

    by Zacks Equity Research

    Zacks.com featured highlights include: Vista Outdoor, Canon, Apollo Medical, Tyler Tech and ResMed

    ResMed (RMD) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    ResMed (RMD) delivered earnings and revenue surprises of 8.00% and 12.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

    Nilanjan Banerjee headshot

    Betting on These 5 Low-Beta Stocks is Ideal in a Choppy Market

    by Nilanjan Banerjee

    It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. VSTO, CAJ, AMEH, TYL and RMD are the frontrunners.

    Abbott (ABT) Receives FDA Approval for OCT Imaging Platform

    by Zacks Equity Research

    The FDA authorization for Abbott's (ABT) OCT imaging platform powered by the Ultreon Software is expected to broaden its accessibility to physicians.

    Trina Mukherjee headshot

    Medical Products' Aug 5 Earnings Roster: BDX, RMD & More

    by Trina Mukherjee

    Let's see how Medical Product companies' stocks like BDX, RMD, CAH, ABMD and XRAY are poised ahead of their earnings releases.

    6 GARP Stocks to Scoop Up for Maximum Returns

    by Zacks Equity Research

    If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

    Earnings Estimates Rising for ResMed (RMD): Will It Gain?

    by Zacks Equity Research

    ResMed (RMD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

    Earnings Preview: ResMed (RMD) Q4 Earnings Expected to Decline

    by Zacks Equity Research

    ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Charles River (CRL) Q2 Earnings to Mirror Broad-Based Demand

    by Zacks Equity Research

    Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.